Profil
Renee T.
Leck is currently the Director of Investor Relations at Orchard Therapeutics Plc.
Previously, she worked as a Senior Manager of Investor Relations at Agios Pharmaceuticals, Inc. from 2015 to 2018.
Aktive Positionen von Renee T. Leck
| Unternehmen | Position | Beginn |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Renee T. Leck
| Unternehmen | Position | Ende |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Public Communications Contact | 01.12.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
